Longtime CEO to leave in 2021, will spend remaining time focused on defending industry from attempts to curtail drug prices
Oct. 11, 2019
By Walt Williams
Jim Greenwood is stepping down as CEO of the Biotechnology Innovation Organization, but will first guide the $79 million-revenue group through an upcoming election season where the price of prescription medications will once again be a hot-button topic.
BIO announced Oct. 8 that Greenwood would leave the association sometime following the 2020 elections, with the CEO staying on through a leadership transition likely to stretch into 2021. The CEO joined BIO in 2005 after having served 12 years in the U.S. House as a Republican from Pennsylvania. In an interview with CEO Update, he said that political background played no small part in his hiring.